[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity
Dawn Halkuff, a director of Xeris Biopharma Holdings, Inc. (XERS), reported a sale of 42,500 shares executed on 08/12/2025 at a weighted average price of $7.2759. The filing states the shares were sold in multiple transactions at prices ranging from $7.190 to $7.450. After the reported dispositions, the filing shows 115,000 shares beneficially owned directly.
The report also discloses an indirect holding of 5,410 shares through the Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 and states the reporting person disclaims beneficial ownership of those trust shares except to the extent of a pecuniary interest. No derivative securities are reported.
Dawn Halkuff, membro del consiglio di Xeris Biopharma Holdings, Inc. (XERS), ha segnalato la vendita di 42,500 azioni eseguita il 08/12/2025 a un prezzo medio ponderato di $7.2759. La nota indica che le azioni sono state cedute in pi霉 transazioni a prezzi compresi tra $7.190 e $7.450. Dopo le disposizioni riportate, la segnalazione mostra 115,000 azioni detenute direttamente.
Il rapporto rivela inoltre una partecipazione indiretta di 5,410 azioni tramite il Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 e specifica che la persona che effettua la segnalazione rinuncia alla titolarit脿 beneficiaria di tali azioni del trust, eccetto nella misura di un interesse pecuniario. Non sono riportati strumenti derivati.
Dawn Halkuff, directora de Xeris Biopharma Holdings, Inc. (XERS), inform贸 la venta de 42,500 acciones ejecutada el 08/12/2025 a un precio medio ponderado de $7.2759. El documento indica que las acciones se vendieron en varias transacciones a precios que oscilaron entre $7.190 y $7.450. Tras las disposiciones notificadas, el informe muestra 115,000 acciones de propiedad directa.
El informe tambi茅n revela una tenencia indirecta de 5,410 acciones a trav茅s del Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 y declara que la persona que informa renuncia a la titularidad beneficiaria de esas acciones del fideicomiso, salvo en la medida de un inter茅s pecuniario. No se informan valores derivados.
Dawn Halkuff電� Xeris Biopharma Holdings, Inc. (XERS) 鞚挫偓搿滌劀 08/12/2025鞐� 臧�欷戫弶攴� 臧�瓴� $7.2759搿� 42,500欤茧ゼ 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 氤搓碃靹滌棎電� 頃措嫻 欤检嫕鞚� 鞐煬 瓯半灅鞐愳劀 $7.190鞐愳劀 $7.450 靷澊鞚� 臧�瓴╈溂搿� 毵る弰霅橃棃雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 觳橂秳 鞚错泟 頃措嫻 氍胳劀鞐愲姅 歆侅爲 鞁れ 氤挫湢頃� 欤检嫕鞚� 115,000欤茧 響滌嫓霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 氤搓碃靹滊姅 霕愴暅 Dawn Halkuff Revocable Trust U/A DTD 08/25/2017鞚� 韱淀暣 5,410欤茧ゼ 臧勳爲 氤挫湢頃橁碃 鞛堨潓鞚� 瓿店皽頃橂┌, 氤搓碃鞚胳潃 旮堨爠鞝� 鞚挫澋鞚� 氩旍渼毳� 鞝滌櫢頃橁碃 攴� 鞁犿儊 欤检嫕鞐� 雽�頃� 靾橃澋鞝� 靻岇湢甓岇潉 攵�鞚疙暅雼り碃 氇呾嫓頃╇媹雼�. 韺岇儩 歃濌秾鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
Dawn Halkuff, administratrice de Xeris Biopharma Holdings, Inc. (XERS), a d茅clar茅 la vente de 42,500 actions ex茅cut茅e le 08/12/2025 au prix moyen pond茅r茅 de $7.2759. Le d茅p么t indique que les actions ont 茅t茅 vendues en plusieurs transactions 脿 des prix compris entre $7.190 et $7.450. Apr猫s les cessions signal茅es, le d茅p么t montre 115,000 actions d茅tenues directement.
Le rapport r茅v猫le 茅galement une d茅tention indirecte de 5,410 actions via le Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 et indique que la personne d茅clarante nie la propri茅t茅 b茅n茅ficiaire de ces actions du trust, sauf dans la mesure d'un int茅r锚t p茅cuniaire. Aucun titre d茅riv茅 n'est d茅clar茅.
Dawn Halkuff, Vorstandsmitglied von Xeris Biopharma Holdings, Inc. (XERS), meldete den Verkauf von 42,500 Aktien, ausgef眉hrt am 08/12/2025 zum gewichteten Durchschnittspreis von $7.2759. Die Einreichung gibt an, dass die Aktien in mehreren Transaktionen zu Preisen zwischen $7.190 und $7.450 ver盲u脽ert wurden. Nach den gemeldeten Ver盲u脽erungen zeigt die Einreichung, dass 115,000 Aktien direkt gehalten werden.
Der Bericht legt au脽erdem eine indirekte Beteiligung von 5,410 Aktien 眉ber den Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 offen und erkl盲rt, dass die meldende Person das wirtschaftliche Eigentum an diesen Treuhandanteilen au脽er insoweit, als ein finanzielles Interesse besteht, bestreitet. Es werden keine derivativen Wertpapiere gemeldet.
- Transparent price disclosure: the filing provides a weighted average sale price and the full reported execution price range
- No derivative transactions reported, keeping ownership changes straightforward
- Director disposition of 42,500 shares, reducing direct holdings to 115,000 shares
- Indirect trust holding of 5,410 shares is disclaimed, limiting clarity on beneficial control beyond pecuniary interest
Insights
TL;DR: Director sold 42,500 XERS shares at ~$7.28 each; direct holdings now 115,000 and 5,410 held indirectly in a trust.
The reported sale reduces the director's direct stake to 115,000 shares following multiple transactions at a weighted average price of $7.2759, with execution prices between $7.190 and $7.450. The filing includes clear price-range disclosure and a weighted-average price, which helps determine realized proceeds but does not by itself indicate intent or material company impact. No derivative activity is listed, limiting complexity of the ownership change. Without company-wide share counts or context, the transaction's market-significance cannot be assessed from this filing alone.
TL;DR: Form 4 discloses an open-market sale by a director and an indirect trust holding; disclosure appears complete for the reported items.
The report documents a straightforward Section 16 disclosure: an open-market sale of 42,500 common shares and an indirect trust position of 5,410 shares. The inclusion of the weighted average price and the price range adds transparency. The filing also contains the reporting-person disclaimer regarding beneficial ownership of trust shares, which is a standard governance disclosure. There are no reported derivative transactions or other arrangements that would complicate the ownership picture.
Dawn Halkuff, membro del consiglio di Xeris Biopharma Holdings, Inc. (XERS), ha segnalato la vendita di 42,500 azioni eseguita il 08/12/2025 a un prezzo medio ponderato di $7.2759. La nota indica che le azioni sono state cedute in pi霉 transazioni a prezzi compresi tra $7.190 e $7.450. Dopo le disposizioni riportate, la segnalazione mostra 115,000 azioni detenute direttamente.
Il rapporto rivela inoltre una partecipazione indiretta di 5,410 azioni tramite il Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 e specifica che la persona che effettua la segnalazione rinuncia alla titolarit脿 beneficiaria di tali azioni del trust, eccetto nella misura di un interesse pecuniario. Non sono riportati strumenti derivati.
Dawn Halkuff, directora de Xeris Biopharma Holdings, Inc. (XERS), inform贸 la venta de 42,500 acciones ejecutada el 08/12/2025 a un precio medio ponderado de $7.2759. El documento indica que las acciones se vendieron en varias transacciones a precios que oscilaron entre $7.190 y $7.450. Tras las disposiciones notificadas, el informe muestra 115,000 acciones de propiedad directa.
El informe tambi茅n revela una tenencia indirecta de 5,410 acciones a trav茅s del Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 y declara que la persona que informa renuncia a la titularidad beneficiaria de esas acciones del fideicomiso, salvo en la medida de un inter茅s pecuniario. No se informan valores derivados.
Dawn Halkuff電� Xeris Biopharma Holdings, Inc. (XERS) 鞚挫偓搿滌劀 08/12/2025鞐� 臧�欷戫弶攴� 臧�瓴� $7.2759搿� 42,500欤茧ゼ 毵り皝頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 氤搓碃靹滌棎電� 頃措嫻 欤检嫕鞚� 鞐煬 瓯半灅鞐愳劀 $7.190鞐愳劀 $7.450 靷澊鞚� 臧�瓴╈溂搿� 毵る弰霅橃棃雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 觳橂秳 鞚错泟 頃措嫻 氍胳劀鞐愲姅 歆侅爲 鞁れ 氤挫湢頃� 欤检嫕鞚� 115,000欤茧 響滌嫓霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 氤搓碃靹滊姅 霕愴暅 Dawn Halkuff Revocable Trust U/A DTD 08/25/2017鞚� 韱淀暣 5,410欤茧ゼ 臧勳爲 氤挫湢頃橁碃 鞛堨潓鞚� 瓿店皽頃橂┌, 氤搓碃鞚胳潃 旮堨爠鞝� 鞚挫澋鞚� 氩旍渼毳� 鞝滌櫢頃橁碃 攴� 鞁犿儊 欤检嫕鞐� 雽�頃� 靾橃澋鞝� 靻岇湢甓岇潉 攵�鞚疙暅雼り碃 氇呾嫓頃╇媹雼�. 韺岇儩 歃濌秾鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
Dawn Halkuff, administratrice de Xeris Biopharma Holdings, Inc. (XERS), a d茅clar茅 la vente de 42,500 actions ex茅cut茅e le 08/12/2025 au prix moyen pond茅r茅 de $7.2759. Le d茅p么t indique que les actions ont 茅t茅 vendues en plusieurs transactions 脿 des prix compris entre $7.190 et $7.450. Apr猫s les cessions signal茅es, le d茅p么t montre 115,000 actions d茅tenues directement.
Le rapport r茅v猫le 茅galement une d茅tention indirecte de 5,410 actions via le Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 et indique que la personne d茅clarante nie la propri茅t茅 b茅n茅ficiaire de ces actions du trust, sauf dans la mesure d'un int茅r锚t p茅cuniaire. Aucun titre d茅riv茅 n'est d茅clar茅.
Dawn Halkuff, Vorstandsmitglied von Xeris Biopharma Holdings, Inc. (XERS), meldete den Verkauf von 42,500 Aktien, ausgef眉hrt am 08/12/2025 zum gewichteten Durchschnittspreis von $7.2759. Die Einreichung gibt an, dass die Aktien in mehreren Transaktionen zu Preisen zwischen $7.190 und $7.450 ver盲u脽ert wurden. Nach den gemeldeten Ver盲u脽erungen zeigt die Einreichung, dass 115,000 Aktien direkt gehalten werden.
Der Bericht legt au脽erdem eine indirekte Beteiligung von 5,410 Aktien 眉ber den Dawn Halkuff Revocable Trust U/A DTD 08/25/2017 offen und erkl盲rt, dass die meldende Person das wirtschaftliche Eigentum an diesen Treuhandanteilen au脽er insoweit, als ein finanzielles Interesse besteht, bestreitet. Es werden keine derivativen Wertpapiere gemeldet.
FAQ
What did Xeris (XERS) director Dawn Halkuff report on 08/12/2025?
How many XERS shares does Dawn Halkuff own after the reported transaction?
At what prices were the XERS shares sold?
Were any derivative securities reported for Dawn Halkuff on this Form 4?
What indirect holdings are disclosed for Dawn Halkuff in the XERS filing?
